CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: Results of a French multicentric study

Annals of Oncology

Volumn 17, Issue 8, 2006, Pages 1234-1238

  Riedinger, J M ^a   Wafflart, J ^b   Ricolleau, G ^c   Eche, N ^d   Larbre, H ^e   Basuyau, J P ^f   Dalifard, I ^g   Hacene, K ^h   Pichon, M F ^h  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e Institut Godinot   (France)

^f CENTRE HENRI BECQUEREL   (France)

^g CENTRE PAUL PAPIN   (France)

^h CENTRE RENÉ HUGUENIN   (France)

Author keywords

CA 125; Ovarian cancer; Survival

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; PLATINUM DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; FRANCE; HALF LIFE TIME; HUMAN; IMMUNOASSAY; KAPLAN MEIER METHOD; LAPAROTOMY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

EID: 33747880168     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl120     Document Type: Article

References (28)

1. Therasse P, Susan G, Arbuck SG et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
2. Van Den Burg MEL, Lammes FB, Van Putten WLJ, Stoter G. Ovarian Cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988; 30: 307-312.
3. Makar AP, Kristensen GB, Kaern J et al. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002-10.
4. Gard GB, Houghton CR. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994; 53: 283-289.
5. Gadducci A, Zola P, Landoni F et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: Results of a Multicentric Italian Study. Gynecol Oncol 1995; 58: 42-47.
6. Munstedt K, Krisch M, Sachsse S, Vahrson H. Serum CA 125 levels and survival in advanced ovarian cancer. Arch Gynecol Obstet 1997; 259: 117-23.
7. Colakovic S, Lukic V, Mitrovic L et al. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000; 15: 147-52.
8. Makar AP, Kristensen GB, Bormer OP, Trope CG. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 1993; 49: 73-79.
9. Frasci G, Conforti S, Zullo F et al. A risk model for ovarian carcinoma patients using CA 125. Time to normalization renders second-look laparotomy redundant. Cancer 1996; 77: 1122-30.
10. Rustin GJS, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-1551.
11. Peters-Engl C Obermair A, Heinzl H et al. CA 125 regression after two completed cycles of chemotherapy: Lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer 1999; 81: 662-666.
12. Bridgewater JA, Nelstrop AE, Rustin GJS et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999; 17: 501-508.
13. Rustin GJS. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21: 187s-193s.
14. Hawkins RE, Roberts K, Wiltshaw E et al. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989; 96: 1395-9.
15. Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69: 423-9.
16. Markowska J, Kopczynski Z, Manys G, Szewierski Z. CA 125 in monitoring chemotherapy of patients with ovarian cancer: Early response to the treatment. Neoplasma 1990; 37: 687-92.
17. Buller RE, Berman ML, Bloss JD et al. CA 125 regression: A model for epithelial ovarian cancer response. Am J Obstetr Gynecol 1991; 165: 360-367.
18. Rosman M, Hayden CL, Thiel RP et al. Prognostic indicators for poor risk epithelial ovarian carcinoma. Cancer 1994; 74: 1323-1328.
19. Buller RE, Vasilev S, DiSaia PJ. CA 125 kinetics: A cost-effectve clinical tool to evaluate clinical trial outcomes in the 1990s. Am J Obstetr Gynecol 1996; 174: 1241-125.
20. Riedinger JM, Barillot I, Coudert B et al. Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV. Bull Cancer 1996; 63: 654-663.
21. Gadducci A, Cosio S, Fanucchi A et al. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 2004; 93: 131-6.
22. Ferrero JM, Largillier R, Ramaioli A et al. Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors. Bull Cancer 1997; 84: 722-728.
23. Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005; 16(1): 47-50.
24. Standards Options et Recommandations. Ovarian Cancer. Kerbrat P, Lhomme C, Fervers B et al. French National Fédération of cancer (FNCLCC). Br J Cancer 2001; 84 Suppl 2: 18-23.
25. International Federation of Gynaecology and Obstetrics (FIGO). Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 263-264.
26. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon 2003.
27. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
28. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc 1972; B 34: 187-220.